Cellectis
CLLS
$2.56
Share price
1.59%
Change (1 day)
31.28%
Change (1 year)
Categories
P/S ratio for Cellectis (CLLS)
P/S ratio as of April 2024 (TTM): 11.4
According to Cellectis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.4271. At the end of 2023 the company had a P/S ratio of 5.36.
P/S ratio history for Cellectis from 2016 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 5.36 | 4.39% |
| 2022 | 5.14 | -23.19% |
| 2021 | 6.69 | -61.66% |
| 2020 | 17.4 | -64.67% |
| 2019 | 49.4 | -13.25% |
| 2018 | 56.9 | 41.84% |
| 2017 | 40.1 | 181.3% |
| 2016 | 14.3 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 7.47 | -34.65% | 🇺🇸 USA |
 uniQure QURE | 13.3 | 16.00% | 🇳🇱 Netherlands |
 Novavax NVAX | 0.8658 | -92.42% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |